Utah is currently home to 1240 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Cord Clamping Among Neonates With Congenital Heart Disease
NCT06153459
Recruiting
The goal of this clinical trial is to compare 2 different timepoints for clamping the umbilical cord at birth for term-born infants with a prenatal diagnosis of congenital heart disease (CHD). The main questions it aims to answer are: Does Delayed Cord Clamping at 120 seconds (DCC-120) or Delayed Cord Clamping at 30 seconds (DCC-30) after birth lead to better health outcomes? Does DCC-120 seconds or DCC-30 seconds after birth lead to better neuromotor outcomes at 22-26 months of infant age (pos... Read More
Gender:
All
Ages:
Between 37 weeks and 42 weeks
Trial Updated:
05/15/2024
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Congenital Heart Disease (CHD)
Register for Updates
A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors
NCT06132503
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize the pharmacokinetics (PK) of LP-284 and to assess clinical activity of LP-284.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: START Mountain Region, West Valley City, Utah
Conditions: Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Register for Updates
Study of LP-184 in Patients With Advanced Solid Tumors
NCT05933265
Recruiting
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: START Mountain Region, West Valley City, Utah
Conditions: Advanced Solid Tumor
Register for Updates
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
NCT05919511
Recruiting
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: cGVHD
Register for Updates
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
NCT05836220
Recruiting
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/15/2024
Locations: Site Number: USA038-2, Saint George, Utah
Conditions: Secondary Hyperparathyroidism, End Stage Kidney Disease
Register for Updates
Myositis Interstitial Lung Disease Nintedanib Trial
NCT05799755
Recruiting
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD). Interstitial lung disease is a disorder caused by the abnormal accumulation of cells structures between air sacs of the lungs resulting in thickening, stiffness and scarring of the tissues of the lung. This study will enroll a total of 134 participants across 15 clinical sites located in the United States. A subset of part... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: University of Utah Health Sciences Center, Salt Lake City, Utah
Conditions: Myositis Associated Interstitial Lund Disease (MA-ILD)
Register for Updates
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
All
Ages:
12 years and above
Trial Updated:
05/15/2024
Locations: University of Utah Clinical Neurosciences Center, Salt Lake City, Utah
Conditions: Primary Generalized Tonic-Clonic Seizures
Register for Updates
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
NCT05369000
Recruiting
This is a phase 1/2a, first-in-human study to evaluate Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207 alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory metastatic castration resistant prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: Metastatic Castration Resistant Prostate Cancer
Register for Updates
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
NCT05346484
Recruiting
This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
Register for Updates
Muscle Blood Flow Regulation in HFpEF
NCT05115890
Recruiting
Heart failure with preserved ejection (HFpEF) disproportionately affects Veterans and is the number one reason for hospital discharge in the VA Health Care System. Exercise intolerance is a common complication experienced by patients with HFpEF, perpetuating physical inactivity and accelerating disease progression. This research proposal aims to elucidate mechanisms responsible for inadequate skeletal muscle blood flow and exercise intolerance in patients with HFpEF compared with healthy control... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah
Conditions: HFpEF
Register for Updates
Models of Primary Osteoporosis Screening in Male Veterans
NCT04079868
Recruiting
Models of Osteoporosis Screening in Male Veterans aims to test 1 distinct care model of primary osteoporosis screening in men within the VA healthcare setting. All care models deliver VA recommended osteoporosis screening and treatment to high-risk Veterans by appropriate Durham VA clinical staff. The MOPS project will evaluate patient, provider and facility outcomes to determine the effectiveness of each intervention.
Gender:
All
Ages:
All
Trial Updated:
05/15/2024
Locations: VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah
Conditions: Osteoporosis, Osteopenia, Osteoporotic Fracture
Register for Updates
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399
Recruiting
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.
Gender:
All
Ages:
30 days and above
Trial Updated:
05/15/2024
Locations: Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Register for Updates